Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

The association between plasma visfatin levels and ED

International Journal of Impotence Research volume 27, pages 157–160 (2015)Cite this article

Subjects

Abstract

Visfatin was initially proposed as a clinical marker of atherosclerosis, endothelial dysfunction and vascular damage, with a potential prognostic value. It has been shown that endothelial dysfunction has an important role in ED. We aimed to determine the levels of visfatin in ED patients and characterize the relationship between visfatin levels and ED. This case–control study was conducted between October 2010 and August 2012, and 41 severe ED patients (group 1) and 36 healthy controls (group 2) were involved. Fasting visfatin level was measured with enzyme-linked immunosorbent assay method. The groups were compared in terms of some clinical (height, weight and body mass index) and biochemical parameters (glucose, triglycerides, cholesterol, low-density lipoprotein and high-density lipoprotein). No statistically significant difference in the visfatin levels was found between the patients and the controls (17, 5±14.4, 14, 9±7 and 9, respectively, P=0.399). No difference in the other clinical and biochemical parameters was observed between the two groups. No significant difference in the serum visfatin levels of ED patients compared with healthy patients was noticed. Further studies are needed to confirm the effect of visfatin on cardiometabolic diseases and ED, indeed.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. NIH Consensus Development Panel on Impotence. JAMA 1993; 270: 83–90.

  2. Lauman EO, Paik A, Rosen RC . The epidemiology of erectile dysfunction: results from the National Health and Social Life Survey. Int J Impot Res 1999; 11 (Suppl 1): S60–S64.

    Article  Google Scholar 

  3. Aytac IA, McKinlay JB, Krane RJ . The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84: 50–56.

    Article  Google Scholar 

  4. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307–312.

    Article  CAS  Google Scholar 

  5. Romacho T, Sánchez-Ferrer CF, Peiró C . Visfatin/Nampt: an adipokine with cardiovascular impact. Mediators Inflamm 2013; 2013: 946427.

    Article  Google Scholar 

  6. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426–430.

    Article  CAS  Google Scholar 

  7. Lamers D, Famulla S, Wronkowitz N, Hartwig S, Lehr S, Ouwens DM et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011; 60: 1917–1925.

    Article  CAS  Google Scholar 

  8. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM . Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319–326.

    Article  CAS  Google Scholar 

  9. Andersson KE, Wagner G . Physiology of penile erection. Physiol Rev 1997; 75: 191–236.

    Article  Google Scholar 

  10. Sullivan ME, Thompson CS, Dashwood MR, Khan MA, Jeremy JY, Morgan RJ et al. Nitric oxide and penile erection: is erectile dysfunction another manifestation of vascular disease? Cardiovasc Res 1999; 43: 658–665.

    Article  CAS  Google Scholar 

  11. Montorsi P, Montorsi F, Schulman C . Is erectile dysfunction the tip of the iceberg of a systemic vascular disorder? Eur Urol 2003; 22: 352–354.

    Article  Google Scholar 

  12. Böhm M, Baumhäkel M, Teo K, Sleight P, Probstfield J, Gao P et al. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials. Circulation 2010; 121: 1439–1446.

    Article  Google Scholar 

  13. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A . The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822–830.

    Article  CAS  Google Scholar 

  14. Chudek J, Adamczak M, Nieszporek T, Wiecek A . The adipose tissue as an endocrine organ — a nephrologists' perspective. Contrib Nephrol 2006; 151: 70–90.

    Article  Google Scholar 

  15. Bessa SS, Hamdy SM, El-Sheikh RG . Serum visfatin as a non-traditional biomarker of endothelial dysfunction in chronic kidney disease: an Egyptian study. Eur J Intern Med 2010; 21: 530–535.

    Article  CAS  Google Scholar 

  16. Pepene CE . Evidence for visfatin as an independent predictor of endothelial dysfunction in polycystic ovary syndrome. Clin Endocrinol 2012; 76: 119–125.

    Article  CAS  Google Scholar 

  17. Song HK, Lee MH, Kim BK, Park YG, Ko GJ, Kang YS et al. Visfatin: a new player in mesangial cell physiology and diabetic nephropathy. Am J Physiol Renal Physiol 2008; 295: 1485–1494.

    Article  Google Scholar 

  18. Ryan JG, Gajraj J . Erectile dysfunction and its association with metabolic syndrome and endothelial function among patients with type 2 diabetes mellitus. J Diabetes Complications 2012; 26: 141–147.

    Article  Google Scholar 

  19. Wierzbicki AS, Solomon H, Lumb PJ, Lyttle K, Lambert-Hammill M, Jackson G . Asymmetric dimethyl arginine levels correlate with cardiovascular risk factors in patients with erectile dysfunction. Atherosclerosis 2006; 185: 421–425.

    Article  CAS  Google Scholar 

  20. Axelsson J, Witasp A, Carrero JJ, Qureshi AR, Suliman ME, Heimburger O et al. Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am J Kidney Dis 2007; 49: 237–244.

    Article  CAS  Google Scholar 

  21. Kim SR, Bae YH, Bae SK, Choi KS, Yoon KH, Koo TH et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kB activation in endothelial cells. Biochim Biophys Acta 2008; 1783: 886–895.

    Article  CAS  Google Scholar 

  22. Yilmaz MI, Saglam M, Carrero JJ, Qureshi AR, Caglar K, Eyileten T et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant 2008; 23: 959–965.

    Article  CAS  Google Scholar 

  23. Elesber AA, Solomon H, Lennon RJ, Mathew V, Prasad A, Pumper G et al. Coronary endothelial dysfunction is associated with erectile dysfunction and elevated asymmetric dimethylarginine in patients with early atherosclerosis. Eur Heart J 2006; 27: 824–831.

    Article  CAS  Google Scholar 

  24. Corona G, Maggi M . The role of testosterone in erectile dysfunction. Nat Rev Urol 2010; 7: 46–56.

    Article  CAS  Google Scholar 

  25. Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 2011; 8: 272–283.

    Article  CAS  Google Scholar 

  26. Corona G, Mannucci E, Fisher AD, Lotti F, Petrone L, Balercia G et al. Low levels of androgens in men with erectile dysfunction and obesity. J Sex Med 2008; 5: 2454–2463.

    Article  CAS  Google Scholar 

  27. Axelsson J, Stenvinkel P . Role of fat mass and adipokines in chronic kidney disease. Curr Opin Nephrol Hypertens 2008; 17: 25–31.

    Article  CAS  Google Scholar 

  28. Heidler S, Temml C, Broessner C, Mock K, Rauchenwald M, Madersbacher S et al. Is the metabolic syndrome an independent risk factor for erectile dysfunction? J Urol 2007; 177: 651–654.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, School of Medicine, Turgut Özal University, Ankara, Turkey

    Ö F Karataş, M E Yıldırım, M Çaviş & E Çimentepe

  2. Department of Biochemistry, School of Medicine, Turgut Özal University, Ankara, Turkey

    H T Celik

  3. Department of Urology, Yüksek İhtisas Training and Research Hospital, Ankara, Turkey

    H Badem

Authors
  1. Ö F Karataş
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M E Yıldırım
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H T Celik
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H Badem
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Çaviş
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E Çimentepe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M E Yıldırım.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Karataş, Ö., Yıldırım, M., Celik, H. et al. The association between plasma visfatin levels and ED. Int J Impot Res 27, 157–160 (2015). https://doi.org/10.1038/ijir.2015.1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijir.2015.1

This article is cited by

Search

Advanced search

Quick links